Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Reaffirms FY 2013 Guidance


Thursday, 24 Jan 2013 07:30am EST 

Celgene Corp affirmed fiscal 2013 guidance and expects total net product sales to increase approximately 11% year-over-year to approximately $6.000 billion and adjusted diluted EPS to increase approximately 13% year-over-year to a range of $5.50 to $5.60. GAAP diluted EPS expected to be in the range of $4.67 to $4.79 for fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.1 billion for fiscal 2013. 

Company Quote

113.35
3.75 +3.42%
26 Dec 2014